Novartis AG Novartis AG

Novartis AG

NVSEF

Rank in Stocks #54
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Share Price
$160.65
Last synced: 2026-11-10
Market Cap
$303.93B
Change (1 day)
-0.20%
Change (1 year)
26.85%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Novartis AG (NVSEF)
Operating Margin as of November 2026 TTM: 30.47%
According to Novartis AG's latest financial reports, its current operating margin (TTM) is 30.47%. At the end of 2025 the company had an operating margin of 31.15%.
Operating Margin history for Novartis AG from 2000 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 30.47% -2.18%
2025 31.15% 10.78%
2024 28.12% 34.29%
2023 20.94% 14.55%
2022 18.28% -20.07%
2021 22.87% 12.38%
2020 20.35% 9.00%
2019 18.67% 2.41%
2018 18.23% -9.08%
2017 20.05% 19.92%
2016 16.72% -6.17%
2015 17.82% -13.83%
2014 20.68% -0.72%
2013 20.83% -5.92%
2012 22.14% 21.92%
2011 18.16% -18.75%
2010 22.35% 0.99%
2009 22.13% 5.13%
2008 21.05% 20.91%
2007 17.41% -20.03%
2006 21.77% -0.46%
2005 21.87% -2.50%
2004 22.43% -0.75%
2003 22.60% -7.34%
2002 24.39% 5.81%
2001 23.05% 4.73%
2000 22.01% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
46.07% -98.49%
US
25.17% -99.17%
US
35.21% -98.84%
US
31.92% -98.95%
CH
13.64% -99.55%
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Novartis AG's operating margin

What is Novartis AG's operating margin?

Novartis AG's operating margin is 30.47%, as of Nov 2026.

What was Novartis AG's operating margin in 2025?

In 2025, Novartis AG's operating margin was 31.15%, compared with 28.12% in 2024.

How has Novartis AG's operating margin changed since 2020?

From 2020 to 2025, Novartis AG's operating margin was highest in 2025 (31.15%) and lowest in 2022 (18.28%).

How does Novartis AG's operating margin compare with similar companies?

Novartis AG's operating margin (30.47%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Eli Lilly and Company, with 46.07%.